List view / Grid view
The ocular injection, now granted its third FDA approval, offers…
The ocular injection, now granted its third FDA approval, offers a more convenient treatment option for patients with vision loss.
Enspryng (satralizumab) significantly reduced relapse in patients with neuromyelitis optica…
Enspryng (satralizumab) significantly reduced relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) in Phase III study.
Phase II/III trial shows Ronapreve significantly reduced viral load in…
Phase II/III trial shows Ronapreve significantly reduced viral load in seronegative patients hospitalised with COVID-19, complimenting previous findings.
